Clinical Trial Update: Managed Access Program Cohort Treatment Plan CTMT212X2002I to Provide Access to Trametinib and Dabrafenib Combination Therapy for Patients With BRAF V600 Mutation-positive Advanced Non-Small Cell Lung Cancer

View source ↗

Summary

Novartis is offering access to the trametinib and dabrafenib combination through a managed access program for patients with BRAF V600 mutation-positive advanced…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Dabrafenib (Dabrafenib)
• Trametinib (trametinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Small Cell Lung Carcinoma | Status: NO_LONGER_AVAILABLE